Unexpected clinical outcome in a patient with liver and brain metastasis from melanoma

Anticancer Res. 2008 Mar-Apr;28(2B):1429-31.

Abstract

The treatment of disseminated melanoma is inadequate. The most active single agents provide brief objective response in 20% of patients, while the combination chemotherapy improves response rates without any apparent survival benefit. Median overall survival is, in fact, 7-9 months and 5 year survival is approximately 6%. Metastatic melanoma with a localization of the disease in the liver and brain are categorized as M1c and have the worst prognosis. Here we describe the history, treatment and favourable clinical outcome in a young man with liver and resected brain metastases who obtained complete remission for 6 years since chemotherapy with dacarbazine, cisplatin and vinblastine.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / secondary*
  • Cisplatin / administration & dosage
  • Dacarbazine / administration & dosage
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / secondary*
  • Male
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Melanoma / secondary*
  • Middle Aged
  • Treatment Outcome
  • Vinblastine / administration & dosage

Substances

  • Vinblastine
  • Dacarbazine
  • Cisplatin